Multiple sclerosis (MS) is driven by immune cells that mistakenly attack myelin — the insulating sheath around nerve fibres in the brain and spinal cord. The vagus nerve does not innervate the central nervous system directly, so its connection to MS might seem remote. Yet the vagus nerve is the body’s primary neural brake on inflammation, and emerging research suggests that impaired vagal function may contribute to the unchecked immune activation that characterises MS.
The Cholinergic Anti-Inflammatory Pathway
The vagus nerve regulates systemic inflammation through the cholinergic anti-inflammatory pathway (CAP), first described by Kevin Tracey and colleagues at the Feinstein Institutes in the early 2000s. The circuit works as follows: vagal afferents detect inflammatory signals in peripheral tissues and relay them to the brainstem. The brainstem responds by sending vagal efferent signals to the spleen and other lymphoid organs, where the nerve terminals release acetylcholine. This acetylcholine binds to alpha-7 nicotinic acetylcholine receptors (alpha7nAChR) on macrophages and other immune cells, suppressing their production of pro-inflammatory cytokines — TNF-alpha, IL-1beta, and IL-6.
In a healthy system, this pathway acts as a thermostat that prevents immune activation from escalating into tissue-damaging inflammation. In MS, this thermostat may be poorly calibrated. Multiple studies have documented reduced vagal tone in MS patients compared with healthy controls, measured through heart-rate variability analysis. Lower vagal tone means weaker anti-inflammatory braking, which could allow peripheral immune activation to persist longer and with greater intensity — potentially increasing the volume of autoreactive immune cells that cross the blood-brain barrier and attack myelin.
Vagal Tone in MS: What the Data Shows
HRV studies in MS populations consistently show reduced parasympathetic indices. A 2021 meta-analysis in Multiple Sclerosis and Related Disorders found that RMSSD (the HRV metric most reflective of vagal tone) was significantly lower in MS patients than in matched controls, and that the reduction correlated with disease duration and disability level. Patients with relapsing-remitting MS showed less vagal reduction than those with secondary progressive MS, suggesting that vagal function deteriorates as the disease advances.
Whether this reduced vagal tone is a cause or consequence of MS remains an open question. It could reflect CNS damage to autonomic centres (the nucleus tractus solitarius and dorsal motor nucleus of the vagus are brainstem structures vulnerable to demyelination). It could also represent a pre-existing vulnerability — individuals with constitutionally lower vagal tone may have weaker anti-inflammatory braking, making them more susceptible to autoimmune disease. Most likely, both mechanisms operate: pre-existing vagal weakness contributes to disease onset, and progressive CNS damage further erodes vagal function, creating a self-reinforcing cycle.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
The Gut-Brain Axis in MS
The vagus nerve is the primary neural pathway connecting the gut microbiome to the brain, and gut dysbiosis is now well-documented in MS. MS patients show altered microbial composition — reduced populations of butyrate-producing bacteria (particularly Faecalibacterium prausnitzii and Butyricicoccus), increased proteobacteria, and altered metabolite profiles. Butyrate and other short-chain fatty acids (SCFAs) activate vagal afferent terminals in the gut and have anti-inflammatory properties; their depletion reduces vagal signalling and removes a brake on systemic inflammation.
A 2023 study in Cell Host & Microbe demonstrated that transferring gut microbiota from MS patients into germ-free mice worsened experimental autoimmune encephalomyelitis (EAE, the standard animal model of MS), while microbiota from healthy donors was protective. The vagus nerve was identified as one of the key communication channels mediating this effect — vagotomised mice showed blunted differences between MS-microbiota and healthy-microbiota recipients, indicating that the vagus nerve transmits at least part of the microbiome’s influence on CNS autoimmunity.
VNS Research in MS
Animal studies. VNS in EAE models has shown consistent benefit: reduced demyelination, decreased inflammatory cell infiltration in the CNS, lower circulating pro-inflammatory cytokine levels, and improved clinical scores (reduced paralysis and motor disability). The effect appears to be mediated primarily through the cholinergic anti-inflammatory pathway — blocking alpha7nAChR abolishes the protective effect of VNS in these models.
Human evidence. Clinical trials of VNS specifically for MS are in early stages. A 2024 pilot study from Amsterdam UMC tested transcutaneous auricular VNS (taVNS) in 20 relapsing-remitting MS patients over 12 weeks. The primary outcomes were safety and tolerability (both acceptable), with secondary outcomes showing reduced serum levels of TNF-alpha and IL-6 and improved fatigue scores compared with baseline. This is preliminary — uncontrolled, small, and short-term — but it establishes that vagal neuromodulation can modulate the immune parameters relevant to MS in human patients.
VNS-paired rehabilitation. A more speculative but intriguing research direction involves pairing vagus nerve stimulation with motor rehabilitation. VNS paired with specific movements has been shown to enhance neuroplasticity in stroke recovery (the Vivistim system has FDA clearance for this indication). Researchers are now investigating whether the same principle could promote remyelination or adaptive neuroplasticity in MS — using vagal stimulation to create a neuroplasticity-enhancing window during which rehabilitation exercises are performed. This is at the conceptual and early preclinical stage.
MS as Autonomic Disease
Beyond its potential role in disease pathogenesis, vagal dysfunction contributes directly to several common MS symptoms. Bladder dysfunction (present in over 80 percent of MS patients) involves disrupted autonomic signalling to the detrusor muscle. Bowel dysfunction, particularly constipation and impaired gastric motility, reflects compromised vagal efferent control of the gastrointestinal tract. Cardiovascular dysautonomia — orthostatic intolerance, exercise intolerance, abnormal blood pressure regulation — involves impaired vagal cardiovascular reflexes.
These autonomic symptoms are frequently undertreated in MS because they do not appear on standard disability scales (the EDSS focuses on motor function and ambulation). Yet they significantly affect quality of life and may respond to interventions that improve vagal function — a treatment avenue that receives less attention than disease-modifying therapies but may be equally important for daily functioning.
Practical Implications
For people with MS, supporting vagal function is not a substitute for disease-modifying therapy but may be a useful adjunct. Regular aerobic exercise — one of the strongest evidence-based interventions for MS symptom management — also increases vagal tone. Dietary strategies that support gut microbial diversity (high-fibre, plant-rich diets that promote SCFA production) address the gut-brain-vagus axis. HRV biofeedback and breathing practices with extended exhalation can directly train vagal tone upward.
The key question for MS research in the coming years is whether restoring vagal anti-inflammatory function can meaningfully slow disease progression — whether the vagus nerve represents a treatable pathway in MS, not just a damaged bystander. The animal data is encouraging. The human data is very early. But the biological rationale is strong, and MS may eventually join epilepsy and depression on the list of conditions where vagal neuromodulation earns a clinical role.
The vagus nerve connects inflammation, immunity, gut health, and brain function into one integrated system — and that integration is especially relevant in autoimmune conditions like MS. For the full science, get the Vagus Nerve & Me eBook.
